We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Panel Accepts One, Rejects Another Daiichi Sankyo Rare Cancer Drug
FDA Advisory Panel Accepts One, Rejects Another Daiichi Sankyo Rare Cancer Drug
The FDA’s cancer drug advisory committee voted Tuesday on two new treatments from Daiichi Sankyo—backing one while giving the thumbs down for the other.